Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis

Akhil Rajendra; Elliot Smith; Maria Agustina Perusini; Kenny Tang; Eshetu G. Atenafu; Aniket Bankar; Steven Chan; Marta B. Davidson; Vikas Gupta; Dawn Maze; Mark D. Minden; Guillaume Richard-Carpentier; Aaron D. Schimmer; Andre C. Schuh; Karen Yee; Hassan Sibai

doi:10.1038/s41408-025-01353-2

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis

Akhil Rajendra
, Elliot Smith
, Maria Agustina Perusini
, Kenny Tang
, Eshetu G. Atenafu
, Aniket Bankar
, Steven Chan
, Marta B. Davidson
, Vikas Gupta
, Dawn Maze
, Mark D. Minden
, Guillaume Richard-Carpentier
, Aaron D. Schimmer
, Andre C. Schuh
, Karen Yee
, Hassan Sibai

Western Sydney University

Research output: Contribution to journal › Article › peer-review

9 Downloads (Pure)

Abstract

Treatment of relapsed-refractory (R/R) FLT3mut AML is an unmet need. Use of gilteritinib monotherapy in the ADMIRAL trial resulted in a modest prolongation of overall survival (OS) from 5.6 months to 9.3 months. Following the results from in-vitro studies showing synergism between gilteritinib and venetoclax, this combination was studied in a phase Ib/II study, resulting in a median OS of 10.0 months.

Original language	English
Article number	143
Number of pages	4
Journal	Blood Cancer Journal
Volume	15
Issue number	1
DOIs	https://doi.org/10.1038/s41408-025-01353-2
Publication status	Published - Dec 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41408-025-01353-2Licence: CC BY-NC-ND

Full textFinal published version, 552 KBLicence: CC BY-NC-ND

Cite this

Rajendra, A., Smith, E., Perusini, M. A., Tang, K., Atenafu, E. G., Bankar, A., Chan, S., Davidson, M. B., Gupta, V., Maze, D., Minden, M. D., Richard-Carpentier, G., Schimmer, A. D., Schuh, A. C., Yee, K., & Sibai, H. (2025). Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis. Blood Cancer Journal, 15(1), Article 143. https://doi.org/10.1038/s41408-025-01353-2

@article{d2091e0e746844b0a695f22e1ab68dee,

title = "Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis",

abstract = "Treatment of relapsed-refractory (R/R) FLT3mut AML is an unmet need. Use of gilteritinib monotherapy in the ADMIRAL trial resulted in a modest prolongation of overall survival (OS) from 5.6 months to 9.3 months. Following the results from in-vitro studies showing synergism between gilteritinib and venetoclax, this combination was studied in a phase Ib/II study, resulting in a median OS of 10.0 months.",

author = "Akhil Rajendra and Elliot Smith and Perusini, \{Maria Agustina\} and Kenny Tang and Atenafu, \{Eshetu G.\} and Aniket Bankar and Steven Chan and Davidson, \{Marta B.\} and Vikas Gupta and Dawn Maze and Minden, \{Mark D.\} and Guillaume Richard-Carpentier and Schimmer, \{Aaron D.\} and Schuh, \{Andre C.\} and Karen Yee and Hassan Sibai",

year = "2025",

month = dec,

doi = "10.1038/s41408-025-01353-2",

language = "English",

volume = "15",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Springer Nature",

number = "1",

}

Rajendra, A, Smith, E, Perusini, MA, Tang, K, Atenafu, EG, Bankar, A, Chan, S, Davidson, MB, Gupta, V, Maze, D, Minden, MD, Richard-Carpentier, G, Schimmer, AD, Schuh, AC, Yee, K & Sibai, H 2025, 'Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis', Blood Cancer Journal, vol. 15, no. 1, 143. https://doi.org/10.1038/s41408-025-01353-2

TY - JOUR

T1 - Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML

T2 - a Canadian single center analysis

AU - Rajendra, Akhil

AU - Smith, Elliot

AU - Perusini, Maria Agustina

AU - Tang, Kenny

AU - Atenafu, Eshetu G.

AU - Bankar, Aniket

AU - Chan, Steven

AU - Davidson, Marta B.

AU - Gupta, Vikas

AU - Maze, Dawn

AU - Minden, Mark D.

AU - Richard-Carpentier, Guillaume

AU - Schimmer, Aaron D.

AU - Schuh, Andre C.

AU - Yee, Karen

AU - Sibai, Hassan

PY - 2025/12

Y1 - 2025/12

N2 - Treatment of relapsed-refractory (R/R) FLT3mut AML is an unmet need. Use of gilteritinib monotherapy in the ADMIRAL trial resulted in a modest prolongation of overall survival (OS) from 5.6 months to 9.3 months. Following the results from in-vitro studies showing synergism between gilteritinib and venetoclax, this combination was studied in a phase Ib/II study, resulting in a median OS of 10.0 months.

AB - Treatment of relapsed-refractory (R/R) FLT3mut AML is an unmet need. Use of gilteritinib monotherapy in the ADMIRAL trial resulted in a modest prolongation of overall survival (OS) from 5.6 months to 9.3 months. Following the results from in-vitro studies showing synergism between gilteritinib and venetoclax, this combination was studied in a phase Ib/II study, resulting in a median OS of 10.0 months.

UR - https://www.scopus.com/pages/publications/105014618495

U2 - 10.1038/s41408-025-01353-2

DO - 10.1038/s41408-025-01353-2

M3 - Article

AN - SCOPUS:105014618495

SN - 2044-5385

VL - 15

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 143

ER -

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this